Medical research published in leading journal reveals promising results for chronic hepatitis B patients using experimental antisense therapy.
Data from two phase 3 clinical trials shows that nearly one in five patients with chronic hepatitis B achieved a functional cure using an experimental treatment called bepirovirsen, according to research presented at the European Association for the Study of the Liver conference.
The figures show that 19% of patients treated with the antisense oligonucleotide bepirovirsen maintained a functional cure 24 weeks after stopping all hepatitis B virus treatment. By comparison, no patients receiving placebo achieved functional cure status during the same period.
The Science Behind the Results
Bepirovirsen works as an antisense oligonucleotide, a type of genetic medicine that targets specific RNA sequences to reduce viral protein production. The treatment represents a different approach compared with current hepatitis B therapies, which typically suppress the virus but rarely eliminate it completely.
A functional cure in hepatitis B means patients have undetectable levels of hepatitis B surface antigen in their blood, indicating the immune system has gained control over the infection. This differs from a complete cure, where all traces of the virus are eliminated from the body.
The B-Well 1 trial results, published in the New England Journal of Medicine, provide the most thorough data yet on this experimental approach. Researchers followed patients for 24 weeks after treatment cessation to assess whether the therapeutic effect persisted.
Current Treatment Landscape
Existing hepatitis B treatments primarily focus on viral suppression rather than cure. Standard antiviral medications can effectively control the infection but typically require lifelong use. The prospect of achieving functional cure represents a significant shift in treatment goals for the estimated 296 million people worldwide living with chronic hepatitis B.
The research suggests that antisense therapy could offer a time-limited treatment option for some patients. Yet the 19% success rate indicates that most patients in the trials did not achieve functional cure, highlighting the need for further research to identify which patients might benefit most from this approach.
What This Means for Kent Residents
Kent residents with chronic hepatitis B should discuss these research findings with their GP or hepatologist, though bepirovirsen remains experimental and is not yet available through NHS services. Those currently managing hepatitis B infection can access specialist care through Kent and Medway NHS services, including hepatology units at Medway Maritime Hospital and East Kent Hospitals. For general health concerns about hepatitis B, residents should contact NHS 111 or speak with their local GP practice about referral options and current treatment availability.
Source: @NEJM
Key Takeaways
- 19% of chronic hepatitis B patients achieved functional cure with bepirovirsen treatment in phase 3 trials
- No patients receiving placebo achieved functional cure during the same study period
- The experimental antisense therapy offers a different approach compared with current lifelong antiviral treatments